Samsung Biologics Co.,Ltd. provided revenue guidance for the year 2021. The annual revenue is expected to remain steady with stable operations across all production facilities, and active pre-sales activities are ongoing for Plant 4 despite the challenging business environment amid the COVID-19 pandemic.